Precision Oncology News

Drug Discovery & Development

News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.

Kronos Bio to Proceed With Phase III Trial of Entospletinib in NPM1-Mutated AML

The trial will be the first AML study to use next-generation sequencing to determine MRD-negative complete response rates as a primary endpoint.

Epizyme Exploring Tazverik Combinations in Basket Trials

The firm is hoping to identify new signals of activity for its lead compound in combination with other agents across a variety of solid and hematologic cancers.

After Setbacks, Innate Pharma on Track to Advance NK Cell-based Immunotherapy Pipeline

Premium

The company's lead candidate lacutamab is moving into the second part of a Phase II trial for biomarker-defined cutaneous T-cell lymphoma patients.

Strata Oncology, Pfizer Partner to Explore New Biomarker Indications for FDA-Approved Drugs

Pfizer is the first drugmaker to join the Strata PATH platform trial and will contribute drugs to advanced cancer patients in four study arms.

Phio, AgonOx Ink T-Cell Immunotherapy Development Pact

Phio will finance the clinical trial slated to start this year and be entitled to future development milestone and sales-based payments from AgonOx.

Feb 26, 2021

Cartesian Therapeutics Bets on mRNA Engineering for Moving CAR T Cells Into Frontline Treatment

Premium

Feb 26, 2021

Elicio Therapeutics Sharpens Development Plan for Cancer Vaccine in KRAS-Mutated Tumors

Premium

Feb 25, 2021

Kronos Bio Doses First Patient in CDK9 Inhibitor Trial With Tempus Performing Sequencing

Feb 25, 2021

Celcuity Prices Upsized Public Stock Offering, Anticipates $24M in Proceeds

Feb 25, 2021

Zentalis Pharmaceuticals, Tempus Partner to Explore WEE1 Inhibitor Activity in Organoid Models

Feb 19, 2021

In Brief This Week: AstraZeneca, Merck, Amgen, Kintara Therapeutics, Dana Farber Cancer Institute

Feb 12, 2021

In Brief This Week: Roche, Novartis, Basilea Pharmaceutica, Revolution Medicines, Genetron Health

Feb 09, 2021

Anticancer Bioscience Raises $10M to Advance Synthetic Lethality Programs

Feb 05, 2021

With First-In-Class Iovance BLA Pending, TIL Therapies on Cusp of Commercialization

Premium

Feb 04, 2021

Revolution Medicines Prices Upsized $260.9M Direct Offering

Feb 04, 2021

InnoCare Begins ICP-192 Study in US in FGFR-Altered Cancers

Feb 03, 2021

Daiichi Sankyo Begins Phase II Patritumab Deruxtecan Study in NSCLC

Feb 02, 2021

Revolution Medicines Looks to Raise $158M in Proposed Public Offering

Jan 29, 2021

In Brief This Week: Janssen, Amgen, Daiichi Sankyo, AstraZeneca, Interpace Biosciences

Jan 28, 2021

ImaginAb, Neuvogen Sign Deal to Use CD8 ImmunoPET Technology in Cancer Vaccine Trials

Jan 26, 2021

Cardiff Oncology to Begin Phase II Onvansertib Trial in Pancreatic Cancer

Jan 22, 2021

Sutro Biopharma Advancing STRO-002 in Phase I Trial With Eye on Biomarker Strategies

Premium

Jan 22, 2021

In Brief This Week: Myriad Genetics, Diaceutics, Agios, Precipio, Lantern Pharma, Guardant Health

Jan 22, 2021

Kuur Therapeutics Reports Initial Activity of CAR NK-Cell Therapy in Neuroblastoma

Jan 21, 2021

Transgene Begins Personalized Cancer Vaccine Study in Head, Neck Cancer